Lake Street raised the firm’s price target on Sight Sciences (SGHT) to $12 from $7 and keeps a Buy rating on the shares. The firm believes the setup for 2026 includes growth from both business segments and new coverage catalysts in the Dry Eye Disease business, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SGHT: